Amylyx Pharmaceuticals & Mass General CENTAUR Trial Evidences Potential for Treating ALS

Amylyx Pharmaceuticals & Mass General CENTAUR Trial Evidences Potential for Treating ALS

The AMG Center for ALS at Mass General recently announced, along with Amylyx Pharmaceuticals, Inc., that AMX0035 demonstrated a significant treatment benefit for people with ALS in the CENTAUR study. The team found that AMX0035 had a statistically significant slowing of ALS disease progression as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) compared to placebo (p<0.05), which was the primary outcome of the study.

Background

Both the commercial biotech (Amylyx) and the research center (Mass General) will submit detailed results from the CENTAUR study to a peer-reviewed publication and  presentation at a future medical congress.

The Drug: AMX0035

AMX0035 is Amylyx’ first-in-class investigational therapy designed to reduce neuronal death and dysfunction. It targets mitochondrial and endoplasmic reticulum-dependent neuronal degeneration pathways. In clinical trials, AMX0035 has overall been shown to be safe and effective. A preclinical study revealed that AMX0035 limited cell death and neurotoxic inflammation in differing ALS models. As reported, CENTAUR had 132 ALS participants to assess the safety and effectiveness of AMX0035. During the study, ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee